All In Biotech

Drug Trial Radar · NCT07391566

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of LPM6690176 Capsules in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Luye Pharma Group Ltd.Industry
Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and Bevacizumab in patients with RAS mutant metastatic colorectal cancer (mCRC), to observe the dose-limiting toxicity (DLT), and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D); Phase 2 is planned to preliminarily evaluate the efficacy of LPM6690176 capsule in combination with chemotherapy + Bev vs. chemotherapy + Bev in patients with previously untreated, RAS mutant mCRC.

Conditions

  • Metastatic Colorectal Cancer (mCRC)

Interventions

  • LPM6690176Drug

    LPM6690176 orally.

  • BevacizumabBiological

    Bevacizumab intravenously

  • FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)Drug

    FOLFIRI intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Dose-limiting toxicities (DLTs)Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)
  2. Phase Ib: Maximum tolerated dose (MTD)Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)
  3. Phase 1b: Recommended Phase 2 Dose (RP2D)Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)
  4. Phase 2: Overall response rate (ORR)Time frame: Approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.